In patients with heart failure (HF), respiratory infections are responsible for acute exacerbation and increased hospitalization. Vaccination may reduce the incidence and/or severity of respiratory infections, and thereby, reduce the risk of HF exacerbation. Despite current recommendation, vaccination coverage (VC) for patients with HF remains far too limited. To study the VC of HF patients followed in our hospital and to precise the strategies desired by the patients in order to carry out the vaccination. This was a prospective monocentric descriptive study conducted between December 2019 and January 2021. Patients with HF history hospitalized in cardiology unit (CU) and patients in a HF telemonitoring program (TP) were included. An interview was conducted by a pharmacist to find out the patient's vaccination status regarding influenza and pneumococcus, together with socio-demographic clinical data. During the interview for non-vaccinated patients, opinion and willingness to be vaccinated were obtained. Data from 335 patients were collected (185 in CU, 150 in TP). The mean age was 69.3 years, and sex ratio was 2.6. About 65% were vaccinated against influenza in the last year (60% in CU, 72% in TP, p=0.022) and 22% had pneumococcal vaccination in the last 5 years (11% in CU, 35% in TP, p<0.001). Respectively 64% of patients with HF with reduced ejection fraction (HFrEF) and 67% of patients with HF with preserved ejection fraction (HFpEF) were vaccinated against influenza (p=0,63) against 25% of patients with HFrEF and 19% with HFpEF for pneumococcus (p=0,27). 68% of the patients were in favour of the vaccination, 23% had a mixed opinion and 9% were against it. Among patients not vaccinated against influenza or pneumococcus, 17% refused to be vaccinated. Among unvaccinated patients who consider vaccination, 69% wanted to be vaccinated by their general practitioner (GP) and 7% wanted to be vaccinated by their cardiologist. Almost 1/3 of unvaccinated patients who were included in CU wanted a vaccine prescription at discharge. Among the vaccinated patients, information on the need to be vaccinated had been provided to them mostly by health insurance (73%) and their GP (19%) for the influenza vaccine and by their cardiologist (55%) and GP (32%) for the pneumococcal vaccination. The VC of HF patients remains insufficient, particularly against pneumococcus, as described by Kopp and al. Patients in TP are more vaccinated than patients in CU, which could involve better management. Moreover, the low rate of vaccinated patients is mainly explained by a lack of awareness, as most of the unvaccinated would like to be vaccinated. About 2/3 of patients wanted to be vaccinated by their GP, and thus play a major role in their global care. The higher vaccination rate for influenza, which unlike pneumococcus benefits from a national vaccination campaign, demonstrates that improvements are needed in the institutional promotion of vaccination for HF patients. Funding Acknowledgement Type of funding sources: None.
All patients with RD (rheumatoid arthritis (RA), spondyloarthropathies (SA) and psoriatic arthritis (PSA)) treated with BT from January 2014 to June 2018 were included.BT optimisation, by dose reduction or prolonging the dosing interval, was indicated when patients had more than 6 months in clinical remission (DAS28 <2.6 for RA and PSA and BAS-DAI <2 for SA) or minimal clinical activity (DAS28 <3.2 and BASDAI <4).Variables were described as frequencies and means. Diagnosis, subcutaneous BT (Abatacept, Adalimumab, Certolizumab, Etanercept, Golimumab, Secukinumab, Tocilizumab and Ustekinumab), dose regimens, total treatment duration, time on BT optimisation (TO) and treatment costs were collected.Cost savings were calculated per patient by comparing optimisation treatment costs to conventional treatment and globally by comparing real cost to theoretical conventional doses cost. Results A total of 448 patients were included in the study, receiving 579 BT treatments. Switching was observed in 29%. From all patients, 47% were in BT optimisation (according to diagnosis: 53.7% with RA, followed by 47.7% with SA and 33.1% with PSA).Sixty per cent of patients with BT optimisation were treated with adalimumab and etanercept, being also the most common BT used in RD treatment.Mean TO duration was 2.2 years. The longest TO were achieved with adalimumab and golimumab (2.7 years) and PSA patients preserved BT optimisation for a mean of 2.8 years.BT optimisation allowed a 50% saving per patient against the use of conventional therapy resulting in a reduction of the total cost of C ¼ 3,000,000 in the past 4 years, which represents a total economic savings of 21%. Conclusion Therapeutic decision-making based on validated disease activity scales has allowed BT optimisation in approximately 50% of patients with RD.Patients remain clinically controlled after BT optimisation for a mean time of 2 years.BT optimisation allows a reduction in costs while maintaining effectiveness.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.